Summary
Colgate-Palmolive Company (CL) has announced a significant change in its Board of Directors. Effective March 15, 2026, Dr. Christopher S. Boerner, currently the Board Chair and CEO of Bristol-Myers Squibb, will join the Colgate-Palmolive Board. Dr. Boerner's extensive experience in global business leadership, particularly within the biopharmaceutical and healthcare sectors, is expected to bring valuable expertise to the company's strategic direction. In conjunction with this appointment, Steven A. Cahillane has informed the Board that he will not seek reelection at the upcoming Annual Meeting of Stockholders on May 8, 2026. This decision is attributed to the increased demands of his new role as CEO of The Kraft Heinz Company. These board-level transitions signal a refresh in leadership perspective and potentially a strengthened focus on areas complementary to Colgate-Palmolive's existing business.
Key Highlights
- 1Christopher S. Boerner, CEO and Chair of Bristol-Myers Squibb, appointed to the Colgate-Palmolive Board, effective March 15, 2026.
- 2Dr. Boerner's appointment brings significant global business leadership and pharmaceutical/healthcare industry expertise.
- 3Steven A. Cahillane will not stand for reelection to the Board at the May 8, 2026 Annual Meeting.
- 4Mr. Cahillane's departure is due to the demands of his new role as CEO of The Kraft Heinz Company.
- 5The Board composition is set to change with the addition of Dr. Boerner and departure of Mr. Cahillane.
- 6Dr. Boerner will receive standard non-employee director compensation.